Abstract
Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early maladaptive schemas seem of importance. Pharmacological treatment includes drugs affecting the serotoninergic, dopaminergic, and glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing that up to 40% of patients with OCD are resistant to the currently available medications, there is a need for novel and effective therapies. Recent discoveries suggest that psilocybin, a non-physically addictive psychoactive substance, may ameliorate disease symptoms. When used in appropriate doses and under strict clinical control, psilocybin appears as a valuable treatment for OCD. This narrative article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Obsessive-compulsive disorder (OCD) is a chronic mental illness that affects approximately 1.6–2.3% of the human population [1]. The course of the disease is troublesome for patients, and, in its severe form, profoundly disturbs their daily activity. Usually, OCD is diagnosed early in life, before adulthood. Patients frequently experience obsessions, defined as recurring thoughts, impulses, needs, and/or compulsions - repeated, forced, and annoying performance of specific activities [1,2,3]. In light of available research, reduction of OCD symptoms can be achieved by modulation of the activity of serotonin- (5-HT), dopamine- and glutamate-mediated neurotransmission systems. However, approximately 40% of patients do not respond properly to the currently available drugs [1]. Hence, there is a need for new, potentially more effective therapeutic methods.
Psychedelics represent hallucinogens that produce false perceptions of non-existing objects or events involving sight, sound, smell, touch, and taste, known as hallucinations. Hallucinogenic substances include two groups of drugs, dissociative - such as dextromethorphan, ketamine, and phencyclidine, and classic - such as serotonergic and dopaminergic hallucinogens [4]. Recent years have brought a surge of data on the clinical use of psychedelic substances, in the therapy of neuropsychiatric conditions. The potential therapeutic applications include depressive symptoms [5, 6] post-traumatic stress disorder [7], substance addiction, pain treatment, and other [4, 8].
Psilocybin, a serotonergic psychedelic substance, induces antidepressant and anxiolytic effects in patients with endogenous depression or other depressive disorders. Improvements in mood and well-being, as well as increased overall life satisfaction, were observed in depressive patients for up to six months after treatment [9]. Over 100 species of mushrooms, mostly from the genus Psilocybe, commonly referred to as “magic mushrooms” or “hallucinogenic mushrooms”, contain psilocybin [10]. After oral intake, psilocybin is converted to its active metabolite, psilocin, in the intestinal mucosa. Both compounds act as agonists or partial agonists of G-protein coupled serotonin (5-HT) receptors, primarily of the inhibitory 5-HT1A and excitatory 5-HT2A/C types. Hallucinogenic actions of psilocybin and its metabolite seem to be mediated mostly through 5-HT2A receptors [11,12,13]. Thus, it was hypothesized that psilocybin may also have a therapeutic potential in OCD. So far, the results of one completed clinical trial and several case reports indicate that psilocybin indeed ameliorates symptoms of this disease [14,15,16,17].
This article provides a thorough overview of OCD’s etiology, current treatment options, and the emerging evidence supporting psilocybin’s efficacy in managing OCD symptoms.
Methods
A comprehensive review of publications, including surveys and systematic reviews, was performed to analyze the role of psilocybin in the management of OCD. Experimental and clinical studies were included, as well as clinical trial data. Articles presenting the putative mechanism of action of psilocybin, and its adverse effects in the context of the pathobiology of OCD were discussed. Scopus and PubMed databases were used to retrieve the articles with the following search terms: psilocybin, obsessive-compulsive disorder, psychedelic. The clinical trial database was also searched.
Psilocybin– pharmacological targets
Psilocybin belongs to the group of psychedelics, acting through serotonergic receptors and thus influencing consciousness. Chemically, psilocybin is a tryptamine that contains an indole ring. The location of the methyl group at the C4 and C5 carbons is characteristic of psilocybin and psilocin, its active metabolite [18]. Psilocin is formed after oral administration of psilocybin by its dephosphorylation in the intestinal mucosa [19]. Psilocybin can be obtained from hallucinogenic psilocybin mushrooms, which have been used by humans for over 3,500 years. The active substance was isolated in 1958 by Albert Hoffmann and was exploited in experimental and clinical research for a short time. Studies on the usefulness of psilocybin largely ceased as a result of the abuse of psychedelics in the 1960s [20]. At that time, in the American legal act - the Controlled Substances Act of 1971 - psilocybin was classified as a Group I agent [12].
Psychedelics, including psilocybin, act on different targets in the serotonergic system. Their primary mechanism of action involves the stimulation of metabotropic 5-HT2A and 5-HT2C receptors, with subsequent activation of the Gα protein, and stimulation of the inhibitory 5-HT1A and 5-HT 1D receptors, linked with the Gi/o protein [18]. The Gα protein increases the synthesis of cAMP (cyclic adenosine monophosphate) and stimulates a variety of intracellular processes, while Gi/o inhibits the formation of cAMP. Other targets of psilocybin and psilocin include 5-HT1B, 5-HT1E, 5-HT2B, 5-HT5A, 5-HT6, 5-HT7, D1, and D3 receptors. Both substances also display a weak affinity towards imidazoline, adrenergic-α2A, -α2B, -α2C receptors, and the SERT transporter [21, 22]. Furthermore, psilocybin enhances intracellular signal transmission by a direct influence on the further steps of signaling cascades, including the early growth response proteins 1 and 2 (EGR1 and EGR2), involved in the modulation of synaptic plasticity and neuronal activity [23].
Psilocybin inhibits the default-mode network (DMN), which is active during the awareness period, but only under calm conditions. Yet, its activity declines when an individual is exposed to various forms of stimulation. This may explain the loss of identity after taking psilocybin. Anatomically, the resting-state network is located in the medial frontal and posterior cingulate cortex [18]. The effects of psilocybin, both psychedelic, and somatic, e.g. nausea, tremor, or cardiovascular effects (Table 1), are mediated mostly by psilocin [24]. Importantly, increased empathy, enhanced well-being, and improved creativity were observed already after the administration of a single dose of psilocybin (1 day after administration: n = 50, 7 days after: n = 22) [25].
The use of psilocybin is practically not associated with the risk of addiction and was suggested as potentially beneficial in the treatment of addictive behaviors [23]. However, medical supervision over drug intake, adequate presentation, and awareness of the risks of medication, along with control of the mental and physical status of the patient can improve the safety of psilocybin for medical purposes [24, 26].
Psilocybin may also be combined with psychotherapy, especially CBT [29, 30]. Psychedelic-assisted psychotherapy is defined as the professionally supervised use of psilocybin and other substances: ketamine, MDMA, LSD, and ibogaine, as part of a psychological intervention [31]. A number of clinical trials reported that psilocybin used in depression and MDMA used in PTSD are safe and effective as add-on treatments [31, 32]. Another randomized controlled trial revealed that psilocybin augments autobiographical recollection, thus supporting the concept that psilocybin is a suitable substance in the course of psychotherapy. Two major benefits of psilocybin use are associated with the reversal of negative cognitive biases. Psilocybin may also aid the recall of salient memories [33].
Obsessive-compulsive disorder
The Diagnostic and Statistical Manual of Mental Disorders (DSM)-5, developed by the American Psychiatric Association in 2013, defines OCD as a condition in which the patient’s obsessions cannot be explained by another mental disorder and are not the body’s response to psychoactive substances or possible illnesses, but, most of all, they are highly burdensome and time-consuming [1].
OCD is characterized by two main components: (a) obsessions, i.e. intrusive thoughts or images recurring without the patient’s will, causing strong feelings and fear, and (b) compulsions, i.e. actions intended to relieve anxiety caused by obsessions [34]. Usually, obsessions and compulsions are related to the fear of contamination - hence the forced and repetitive washing, soaping, cleaning of touched surfaces, avoiding touching objects, changing clothes multiple times during the day, etc. Obsessions can also involve the need for symmetry and order with a subsequent urge to arrange surrounding objects always in the same configuration. A disorderly environment brings profound fear and may even be perceived as a factor leading to the loss of health or life that may happen to patients and their relatives. Various rituals are performed to prevent potential harm, including e.g. checking dozens of times whether the oven is turned off, touching the wall of the room a certain number of times before leaving the house, repeatedly checking whether the entrance door is closed, etc. Unstoppable accumulation of even unnecessary items and a huge difficulty in getting rid of them (hoarding) is also frequent [35, 36]. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [37] divides manifestations of OCD into categories that can be assigned to five groups, presented in Table 2.
Etiology of OCD
The development of OCD is multifactorial and involves psychological aspects and changes in the structure and functioning of the brain. In the emotional sphere of OCD development, 18 dysfunctional cognitive patterns (Early Maladaptive Schemas - EMS) have been described [38]. EMS, according to the schema theory of the American psychologist Jeffrey Young, are dysfunctional themes relating to the patient and his environment, developed in childhood as a response to unsatisfied emotional needs. They consist of memories, beliefs, bodily sensations, and emotions. EMS has been divided into 5 domains according to Young’s schema theory [39], see Fig. 1 for details.
OCD is hereditary in 27 to 45% of cases [1,2,3]. Studies in animal OCD models identified two possible risk genes for OCD: SAPAP3 (SAP90/PSD95-associated protein 3) and SLITRK5 (SLIT And NTRK Like Family Member 5) [40, 41]. Other risk genes include: CHD8 (Chromodomain Helicase Animal Models for OCD Research DNA Binding Protein 8), associated also with autism, and SCUBE1 (Signal Peptide, CUB Domain and EGF Like Domain Containing 1), crucial to the central nervous system development [42,43,44]. SLC1A1 (solute carrier family 1 member 1), encoding the neuronal glutamate transporter 3 (EAAT3), and other gene variants influencing this gene’s expression were also linked to OCD [41, 45].
Altered neurotransmission, especially within cortico-subcortical loops, such as the cortico-striato-thalamo-cortical (CSTC) circuits, was implicated in the development of OCD [35, 46, 47]. CSTC circuits are responsible for motor and cognitive functions such as motivation and reward, response inhibition, and habitual behavior [35, 47, 48]. Projections from regions of the frontal cortex target the striatum, and then, via direct and indirect pathways through the basal ganglia, reach the thalamus and loop back to the cortex [49]. The direct pathway increases, while the indirect pathway decreases cortical excitation. OCD development is thought to be due to the direct pathway overactivity, and, in consequence, from hyperactivity of the CSTC circuits [35, 50].
Several structural alterations were detected in the brains of OCD patients. In a mega-analysis, an increased cerebellar volume and reduced sizes of the dorsomedial prefrontal cortex and the bilateral insular opercular region were detected in OCD patients (n = 412) compared to healthy subjects (n = 368)) [2, 51]. Furthermore, decreased cortical thickness in the superior and inferior frontal, precentral, posterior cingulate, middle temporal, inferior parietal, and precuneus gyri was described [52]. Larger volume of the putamen and decreased volume of the hippocampus were detected in adults with OCD. In child-onset OCD, thalamus volume was larger in untreated than in medicated children [53]. Increased volume of the white matter, especially in the anterior midline tracts, was also demonstrated [54]. Overall, these observations suggest neurodevelopmental changes in OCD [2].
Functional analyses demonstrated increased activity in response to symptom provocation or emotional processing in various brain regions: the orbitofrontal cortex, anterior cingulate cortex, ventral frontostriatal temporal region (e.g. hippocampus), ventromedial prefrontal cortex, middle temporal and left inferior occipital cortex, the bilateral amygdala and right putamen [55, 56]. In general, OCD patients display overactivation of brain areas engaged in arousal and habitual responses, whereas regions responsible for cognitive control are underactivated [57]. Caudate nucleus hyperactivation in OCD patients also implies increased habit formation [58]. The feeling of disgust is abnormally processed in the insula of contamination-related OCD patients [59].
At the molecular level, disturbances in serotonergic, dopaminergic, and glutamatergic transmission in the CSTC loops are associated with the development of OCD [2]. Proposed changes in signaling which are probably engaged in the development of OCD are depicted in Fig. 2 (Fig. 2).
The involvement of 5-HT in OCD pathogenesis is well substantiated. Serotoninergic neurons in the raphe nuclei (RN), dorsal (DRN), and median (MRN) project to nearly all parts of the brain. The RN controls emotions, learning, memory, locomotion, respiration, reproduction, or the sleep-wake cycle [60]. Reciprocal connections between 5-HT neurons of the DRN and the orbital cortices are thought to play a vital part in mood regulation, and thus, dysfunction of this loop was implied in OCD and depression [61]. Enhanced functional connectivity between the RN and temporal cortices, including the middle temporal and paracingulate gyri, amygdala, hippocampus, putamen, thalamus, and brain stem, was observed in patients with OCD [44]. Hyper-connectivity of the RN with the left middle temporal gyrus was also linked with the severity of OCD symptoms and was a significant predictor of response to 16-week SSRI therapy [62].
A significant decrease in mesencephalic serotonin transporter (SERT) binding was shown in 140 patients suffering from OCD [63]. Most studies demonstrated reduced brain SERT binding capacity in the midbrain, brainstem, thalamus, hypothalamus, limbic and paralimbic brain areas, nucleus accumbens, striatal regions, and insular cortex [64,65,66]. Others have reported normal [67] or even elevated [68] SERT binding. However, the groups of patients were much smaller in those single studies (n = 11 and n = 19, respectively). A negative correlation between OCD symptom severity and SERT availability was also detected [69,70,71]. Recent data have shown that SERT availability is reduced in late-onset but not in early-onset OCD [66]. Considering the above, selective serotonin reuptake inhibitors (SSRIs) are recommended as a first-line pharmacotherapy in moderate and severe OCD [72, 73].
The data on dopaminergic involvement in OCD are not fully clear. Dopamine agonists targeting the basal ganglia were shown to generate OCD-like behaviors in animals (quinpirole) and humans (methylphenidate and dextroamphetamine) [74, 75]. On the other hand, some studies have shown that increased cortical dopamine may improve symptoms of OCD [35, 76]. Striatal D2 receptor density was decreased, based on a retrospective analysis of positron emission tomography (PET) and single-photon emission tomography (SPECT) studies in 54 patients [63]. An increased dopamine transporter density was found in the basal ganglia of OCD patients [35, 77,78,79]. In general, dopaminergic activity seems to be enhanced in the course of OCD, and, indeed, antipsychotic drugs may improve OCD symptoms, especially compulsions and habitual behavior [35].
Glutamate plays a vital role in the physiological development of CSTC circuits and helps keep a balance between direct and indirect pathways [80]. Glutamatergic transmission disruptions in the CSTC circuit were proposed to be one of the pathogenetic mechanisms of OCD [81]. Lamotrigine, able to reduce the synaptic glutamate release, was shown to reduce both obsessions and compulsions. Topiramate, blocking kainate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors may also have a positive effect on OCD patients, though the data so far are inconclusive [82]. However, as lamotrigine and topiramate act also as voltage-gated sodium channel antagonists and the latter may stimulate γ-Aminobutyric acid a (GABAa) receptors, it is not fully clear whether their activity in OCD indeed results from changes in glutamate-mediated neurotransmission. Supporting the role of glutamate, presynaptic 5-HT1B receptors are involved in controlling cortical and thalamic glutamatergic input to the basolateral amygdala, an area shown to be impaired in OCD [83]. Furthermore, several neuroimaging studies suggest a dysfunction in the postsynaptic glutamate signaling in the development of OCD [82]. Also, a sequence variation in SLC1A1, encoding the neuronal glutamate transporter 3 (EAAT3), was linked with susceptibility to OCD, particularly in males [45].
Treatment of obsessive-compulsive disorder
The first-line treatment of OCD is cognitive-behavioral psychotherapy [84]. The therapy is based on the assumption that people’s behaviors and emotions depend on the acquired pattern of response to the environment and encountered situations. Initially, a negative thought pattern causing unwanted emotions and behaviors is identified. Treatment focuses on amending the patient’s incorrect reception and analysis of the information from the environment. When inaccurate beliefs are identified, they can be replaced with more appropriate and favorable views [85]. The form of cognitive behavioral therapy (CBT) most commonly used for OCD is exposure and response/ritual prevention (E/RP) therapy [86]. Conscious confronting of obsessive thoughts and situations that provoke obsessions is essential to abandon the obsessive action, even if such a thought/need arises. E/RP psychotherapy significantly reduces symptoms and is even more effective than pharmacological treatment. However, the costs of therapy are high, treatment is not available to every patient, and some patients are apprehensive about therapeutically induced anxiety [84].
Pharmacological treatment of OCD remains a challenge. Furthermore, detailed studies of response to applied pharmacotherapy are complicated by the fact that placebo response seems to affect in part the outcome of clinical trials [87]. Currently, first-line therapy includes the administration of SSRIs such as fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram. SSRIs reduce the 5-HT reuptake into neurons as a result of inhibition of the 5-HT transporter– SERT [88, 89]. SSRIs are used in monotherapy in patients poorly responding to or not willing to receive psychotherapy [84]. However, almost half of the patients initially do not respond to SSRI treatment. In these situations, the dose of the drug is gradually increased, often with good results. If treatment continues to fail, switching to another SSRI or drugs with a different mechanism of action is advised [90]. Yet, in a clinical scenario, higher doses of serotoninergic drugs increase the risk of adverse effects, caused by increased 5-HT1A and 5-HT2A receptor activity, such as changes in mental status, neuromuscular and autonomic hyperactivity, known as the serotonin syndrome [91].
When first-line drugs are ineffective, second-line treatment is introduced. SSRIs can be either switched to another SSRI, to clomipramine (a tricyclic antidepressant, TCA), or to venlafaxine (a serotonin-norepinephrine dual reuptake inhibitor) [92,93,94,95,96,97]. Switching between SSRIs brings improvement in only about 20% of patients, and the use of TCAs is associated with numerous side effects, such as tachycardia, constipation, xerostomia, impaired liver function, and lower seizure threshold. Venlafaxine on the other hand, with a similar effectiveness profile as SSRIs, is much better tolerated than clomipramine [84].
Other drugs interacting with serotoninergic neurotransmission were evaluated in the treatment of OCD, however, their effectiveness was not confirmed clinically [98]. Buspirone, a 5-HT1A receptor agonist, was added to SSRI treatment in two studies (n = 14 in both), but its effectiveness was not higher than placebo [99, 100]. Its addition to clomipramine was not found to be effective either [98, 101]. Pindolol, a non-selective beta-blocker and 5-HT1A receptor antagonist, demonstrated a statistically insignificant trend toward reducing symptoms of OCD (data from randomized placebo-controlled trials) in a meta-analysis of clinical experimental data [102]. Ondansetron, an antiemetic 5-HT3 receptor antagonist, was effective even at low doses, as shown in a systematic review of five controlled studies [103]. Nevertheless, the clinical trial has not met its primary efficacy endpoint [90]. Mirtazapine, a α2 receptor agonist and 5-HT 2 A/C and 5-HT3 antagonist, may be beneficial in OCD treatment or may quicken the response to a concurrent SSRI, according to two controlled studies [104, 105]. Still, more research is needed on this topic [90].
Synergistic treatment in OCD therapy is also attempted, as well as administering drugs acting on other neurotransmitter systems, e.g., the dopaminergic system. Antipsychotics such as aripiprazole, haloperidol, and risperidone, turned out to be more effective than placebo in the treatment of OCD, according to a meta-analysis [106].
Recent years have brought an increasing number of studies exploiting the utility of glutamate antagonists in OCD. Two antiepileptic agents, lamotrigine and topiramate, have shown some promising results in OCD [82, 84]. Both drugs inhibit voltage-gated sodium channels and reduce glutamate outflow, however, it is not clear whether their effects in OCD are linked with the modulation of glutamate-mediated neurotransmission [82, 84].
Memantine is a non-competitive antagonist of the N-methyl-d-aspartic acid (NMDA) receptor ion channel, used in the treatment of Alzheimer’s disease It displayed efficacy as an add-on therapy in moderate to severe OCD, as revealed by two randomized clinical trials [107]. However, the methodology of these studies was questioned [90, 108]. Clinical studies with larger cohorts, properly randomized and with well-defined populations of OCD patients, should be performed.
The benefits associated with the use of ketamine and esketamine as rapid-onset antidepressants are well substantiated [109, 110]. Ketamine, a derivative of phencyclidine, belongs to the group of dissociative psychedelics and displays a high affinity for the phencyclidine site of the NMDA receptor. Inhibition of NMDA receptors on GABAergic interneurons leads to a surge of glutamate and increases neuronal activity in the prefrontal cortex at low doses [111]. The use of ketamine and esketamine seems promising also in the therapy of less severely affected or unmedicated patients with OCD [112]. Therapeutic effects develop rapidly, in contrast to e.g. SSRIs, and the drugs can be used for a limited period of time, which improves patient compliance [82, 112, 113].
Psilocybin in the treatment of OCD
In the search for a more effective pharmacological OCD therapy, psilocybin appears as an interesting, novel alternative. Although still rather limited, the results of experimental research, clinical case reports, and data from one clinical trial consistently indicate that psilocybin may be of value in the therapy of OCD. At present, seven other clinical trials are underway to verify the therapeutic potential of psilocybin in OCD [114,115,116,117,118,119,120].
In animal models of OCD, psilocybin was shown to be effective already after a single administration. A structure-activity relationship study of some psilocin and psilocybin derivatives revealed that in the mouse model of this disease, based on 5-HT-evoked itching, psilocybin, and psilocin, as well as 1-methylpsilocybin, in the doses of 5 mg/kg i.p., reduced the number of scratching episodes. The effect was not linked with 5-HT2C receptors, as the activity of the studied substances in the OCD model did not correlate with the receptor affinity [121]. Another animal model of OCD employs so-called “marble burying” which represents the compulsive behavior of animals. Oral administration of the pulverized mushroom Psilocybe argentipes, with a high content of psilocybin, significantly reduced the number of compulsive marble-burying episodes [122]. In this model, administration of a 5-HT2 antagonist did not alter the activity of psilocybin. Similarly, a recent study in mice, using the marble burying model, showed that neither the 5-HT1A nor the 5-HT2A or 5-HT2C receptors mediate the therapeutic effects of psilocybin [123]. Other studies also demonstrated that the reduction of digging evoked by psilocybin (2 mg/kg) was not reversed by the blockade of 5-HT2A or 5-HT2C. Thus, an alternative mechanism seems to underlie the activity of psilocybin [124]. Its beneficial effects in OCD may result from targeting other serotoninergic receptors, interaction with the SERT transporter, or, possibly, with the dopaminergic receptors D1 and D3.
The first clinical report on the positive effect of psilocybin in OCD dates back to 1959 [125]. Case reports presenting significant improvement of OCD symptoms in patients taking psilocybin or mushrooms containing psilocybin followed [14, 15, 126,127,128]. Regardless of the type of OCD, psilocybin intake significantly reduces or even completely abolishes symptoms. The duration of therapeutic effects in individual patients varied from 4 to 5 days to three weeks without OCD symptoms [14, 15, 127]. In a patient consuming psilocybin mushrooms for four years, symptoms resolved completely during the first two years of the use of this substance. However, later on, OCD symptoms began to reoccur and they gradually returned to baseline levels [128].
So far, one clinical trial addressing the effects of psilocybin on OCD has been completed, but it was conducted on a small group of patients. This double-blind study included nine individuals who received up to 4 doses of psilocybin, at intervals of at least a week. Doses were ascending, from low (100 µg/kg) and medium (200 µg/kg) to high (300 µg/kg). In addition, a very low dose (25 µg/kg) was administered to patients at a random timepoint after the first dose, with the appropriate intervals kept.
The severity of OCD symptoms was evaluated at 0, 4, 8, and 24 h using the Y-BOCS scale. Symptom intensity decreased in all patients, by 23–100%. For most patients, improvement was still present at the 24-hour assessment. No significant adverse effects were observed, apart from a transient increase in blood pressure detected in one patient [16].
There are currently seven clinical trials concerning this topic underway. The study “Psilocybin for Treatment of Obsessive Compulsive Disorder (PSILOCD)” is no longer recruiting new participants [115]. Three other studies (“Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study”, “Effects of Psilocybin in Obsessive Compulsive Disorder” and “PsilOCD: A Pharmacological-Challenge Feasibility Study”) are still recruiting patients [114, 116, 117]. For the first of them, a protocol describing the plan for carrying out research procedures has already been published. The study involves 30 adults who have failed standard treatment at least once and is randomized, double-blind, placebo-controlled (niacin), and non-crossover [129]. A protocol is also available for “PsilOCD: A Pharmacological-Challenge Feasibility Study”, which is a randomized, waitlist-controlled trial with blinded ratings [130]. The studies “Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD”, “Effects of Repeated Psilocybin Dosing in OCD” and “Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD” have not yet started recruiting participants [118,119,120]. Detailed data regarding these studies are provided in Table 3. A case report describing one of the participants (trial NCT03356483) has already been published, revealing a significant reduction of OCD symptoms after treatment [17].
It is noteworthy that psilocybin and psychedelics manifest therapeutic effects already after a single administration. Neurobiological data indicate that increased resting-state functional connectivity (RSFC) was observed within the DMN after discontinuation of treatment in patients with depression [131]. Increased ventromedial prefrontal cortex-bilateral inferior lateral parietal cortex RSFC was predictive of treatment response at 5 weeks, similarly to decreased parahippocampal-prefrontal cortex RSFC [131]. Similarly, alterations in connectivity were observed after the administration of lysergic acid diethylamide (LSD) [132].
In terms of cellular targets, it was suggested that tolerance to stress is mediated by the postsynaptic 5-HT1A receptor, whereas actively addressing a source of stress is mediated by the 5-HT2A receptor and linked with enhanced plasticity. It was proposed that the 5-HT1A receptor pathway is enhanced by the SSRIs, while the 5-HT2A receptor pathway is enhanced by 5-HT2A receptor-agonist psychedelics, such as psilocybin [133]. Effector pathways downstream of serotonin 5-HT2A receptor activation influence, among others, the gene expression patterns [134]. Notably, immediate early genes involved in neuroplasticity, such as egr1 and cfos, or brain-derived neurotrophic factor (BDNF) are rapidly activated after psilocybin [135]. Induced neuroplastic changes in the prefrontal cortex with subsequent functional and structural alterations may help to restore proper brain function [136]. It is feasible that similar changes contribute to the improvement of OCD symptoms following psilocybin administration.
Interestingly, psychedelic experiences were demonstrated to help restoration of individual values and to promote social and pro-environmental attitudes. They seem to be driven by psychological insights [137,138,139]. Such a transformative epiphanic experience may be one of the factors contributing to a possible therapeutic effect of psilocybin and psychedelics in OCD.
Adverse effects of psilocybin therapy
A recent meta-analysis revealed that the acute adverse effects associated with the use of psilocybin include headache, nausea, anxiety, dizziness, and elevated blood pressure. However, they seemed to be tolerable and receded within 48 h [140]. Available experimental data do not provide clear information on the potential cardiovascular effects and toxicity of psychedelics, including psilocybin. The drug seems relatively safe when tested in healthy volunteers [141]. Nevertheless, the use of substances is contraindicated in patients with uncontrolled hypertension [142, 143].
Although considered a rather safe low-toxicity hallucinogen, psilocybin is not devoid of potentially harmful adverse effects. The so-called “bad trip”, or “terrible excursion”, a phenomenon that occurs after the abuse of a psychoactive substance, is one of the most harmful consequences of psilocybin intake. Psychotic symptoms such as hallucinations and delusions, feelings of derealization (a sense of change, distance, and/or unreality of the surrounding world) and depersonalization (an altered sense of oneself as a person), anxiety, or panic attacks may be potentially dangerous for the patient. A “bad trip” has been described as an extremely unpleasant physical experience and is also common after the intake of lysergic acid diethylamide (LSD) [24, 26].
Hallucinogen-induced perceptual disorder, consisting of chronic visual hallucinations: optical snow, changes in color perception, diplopia, or a perceptive dysfunction, e.g. tinnitus, is another serious complication of psilocybin use. Depersonalization and derealization were also described. Two forms of this perceptual disorder, chronic and short (flashbacks) are known; they may last from weeks, months, years, or even up to a lifetime [144, 145].
Self-mutilation and other self-destructive behaviors were also reported in people with mental illnesses taking hallucinogenic mushrooms. Therefore, an absolute contraindication for the use of psilocybin is the history of psychotic events, as well as active schizophrenia and bipolar disorder, also in first-degree relatives. Manic symptoms (extreme talkativeness, agitation, decreased need for sleep, racing thoughts) may also be exacerbated in patients taking psilocybin [24, 26, 143, 146].
In OCD, the administration of psilocybin may induce minor adverse effects. Single reports describe psychedelic visions, nausea, vomiting, and dizziness immediately after consumption of mushrooms (one patient) [127]. Unpleasant sensations such as increased anxiety and a four-hour feeling of dissociation were reported by another patient [14]. It is of interest that several OCD patients who abused other psychoactive substances (e.g. cocaine and/or amphetamines) experienced actual worsening of disease symptoms [126, 127].
Criteria for including patients in psilocybin pharmacotherapy were proposed recently. They are based on intrapersonal and interpersonal factors and have been added to the criteria already used in psychiatric diagnosis. The three most important areas in patient evaluation have been suggested - clinical picture, therapeutic alliance, and patient safety. Implementing such procedures aims to improve treatment safety, patient care, and therapy outcomes [147].
After the promising results of a small clinical trial and positive conclusions from case reports, the results of further ongoing studies should be closely followed. Their outcome will hopefully allow to unequivocally answer the question of whether psilocybin is worth implementing in the treatment of OCD.
Concluding remarks
OCD is a heterogeneous disorder with various symptom dimensions and underlying psychopathological and biological mechanisms. According to Stein et al. [2], OCD can be categorized into different symptom groups: contamination, harm-related, unacceptability, symmetry, and hoarding symptoms. These subgroups may also differ in their response to traditional treatments and may present unique challenges in clinical management.
Application of Psilocybin in OCD Subgroups:
-
1.
Symptom Dimensions and Treatment Response:
-
a.
Contamination and Harm-Related Symptoms: Patients with contamination or harm-related obsessions and compulsions might respond differently to serotonergic interventions compared to those with symmetry or hoarding symptoms. The psilocybin’s agonistic action on 5-HT2A receptors might be particularly beneficial for these subgroups, which are often resistant to SSRIs.
-
b.
Symmetry and Hoarding Symptoms: These subgroups might have different neurobiological underpinnings, such as altered cortico-striato-thalamo-cortical (CSTC) circuitry and dopamine dysregulation. Psilocybin affects multiple neurotransmitter systems, including serotonin and dopamine, which could potentially benefit these patients.
-
2.
Comorbidities:
-
a.
Depression and Anxiety: Comorbid depression and anxiety are common in OCD patients and can complicate treatment. Psilocybin has shown promise in alleviating depressive symptoms and could offer dual benefits for patients with comorbid conditions.
-
b.
Substance Use Disorders: Given that psilocybin is non-addictive and has been proposed as a treatment for addictive behaviors, it could be a suitable option for OCD patients with comorbid substance use disorders.
-
3.
Early Maladaptive Schemas (EMS):
Early Maladaptive Schemas (EMS) are dysfunctional cognitive patterns developed in response to unmet emotional needs during childhood. Psilocybin’s ability to induce introspection and alter cognitive patterns might help patients reframe these maladaptive schemas.
Clinical Application and Considerations:
-
1.
Personalized Treatment:
Given the heterogeneity of OCD, a personalized approach to treatment is essential. Clinicians should consider the specific symptom dimensions, comorbidities, and individual patient profiles when evaluating the potential use of psilocybin.
-
2.
Clinical Trials and Subgroup Analysis:
Future clinical trials should include subgroup analyses to determine the efficacy of psilocybin across different OCD symptom dimensions and comorbid conditions. This would help identify which subgroups benefit the most from psilocybin therapy.
-
3.
Safety and Monitoring:
Strict clinical supervision is vital when using psilocybin. For patients with comorbidities, particularly those with a history of psychotic disorders or bipolar disorder, careful monitoring is crucial to prevent adverse effects.
-
4.
Combination Therapies:
Psilocybin might be used in combination with other therapies, such as cognitive-behavioral therapy and other pharmacological agents. For example, combining psilocybin with exposure and response prevention (E/RP) therapy could enhance treatment outcomes.
-
5.
Patient Education and Informed Consent:
Educating patients about the potential benefits and risks of psilocybin therapy is vital. Informed consent should include a discussion on the current state of research, potential side effects, and the importance of medical supervision.
Future directions
Although experimental data are increasing, the clinical research on psilocybin in OCD is still limited and the evidence base is relatively small. There is a need for large, prospective trials evaluating the usefulness of psilocybin in therapy of OCD. Yet, incorporating psilocybin into clinical practice requires a nuanced understanding of OCD’s heterogeneity. By considering the different symptom dimensions, comorbidities, and individual patient profiles, clinicians can better evaluate the potential benefits of psilocybin therapy. Future research should focus on subgroup analyses in clinical trials and the development of personalized treatment protocols to optimize outcomes for OCD patients.
Limitations
We are aware that still relatively small evidence base including several experimental research articles, case studies and a small clinical trial is a limitation of our study. However, the available data consistently indicate that psilocybin is an interesting therapeutic option as a sole or add-on treatment for OCD patients. Large-scale randomized controlled trials and long-term studies on the safety and efficacy of psilocybin are needed to clarify the value of psilocybin in the management of OCD.
Data availability
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Abbreviations
- 5-HT:
-
Serotonin
- AMPA:
-
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- Amyg:
-
Amygdala
- BDNF:
-
Brain-derived neurotrophic factor
- cAMP:
-
Cyclic adenosine monophosphate
- cfos:
-
C-fos proto-oncogene
- CBT:
-
Cognitive behavioral therapy
- CHD8:
-
Chromodomain helicase animal models for OCD research DNA binding protein 8
- CSTC:
-
Cortico-striato-thalamo-cortical
- DMN:
-
Default-mode network
- DRN:
-
Dorsal raphe nucleus
- DSM-5:
-
Diagnostic and Statistical Manual of Mental Disorders-5
- E/RP:
-
Exposure and response/ritual prevention
- EAAT3:
-
Neuronal glutamate transporter 3
- EGR1:
-
Early growth response proteins 1
- EGR2:
-
Early growth response proteins 2
- EMS:
-
Early Maladaptive Schemas
- FC:
-
Frontal cortex
- GABA:
-
γ-Aminobutyric acid
- HIPP:
-
Hippocampus
- HT:
-
Hypothalamus
- IC:
-
Insular cortex
- LS:
-
Limbic system
- MRN:
-
Median raphe nucleus
- MTG:
-
Middle temporal gyrus
- NAc:
-
Nucleus accumbens
- NMDA:
-
N-methyl-d-aspartic acid
- OCD:
-
Obsessive-compulsive disorder
- OFC:
-
Orbitofrontal cortex
- PAC:
-
Paracingulate gyrus
- PET:
-
Positron emission tomography
- PU:
-
Putamen
- RN:
-
Raphe nuclei
- RSFC:
-
Resting-state functional connectivity
- SAPAP3:
-
SAP90/PSD95-associated protein 3
- SCUBE1:
-
Signal peptide, CUB domain and EGF like domain containing 1
- SERT:
-
Serotonin transporter
- SLC1A1:
-
Solute carrier family 1 member 1
- SLITRK5:
-
SLIT And NTRK like family member 5
- SPECT:
-
Single-photon emission tomography
- SSRIs:
-
Selective serotonin reuptake inhibitors
- STR:
-
Striatum
- TCA:
-
Tricyclic antidepressant
- THA:
-
Thalamus
- Y-BOCS:
-
Yale-Brown Obsessive-Compulsive Scale
References
Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, et al. Use of Selective Alternative therapies for treatment of OCD. Neuropsychiatr Dis Treat. 2023;19:721–32.
Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5(1):52.
Hauser TU. On the development of OCD. Curr Top Behav Neurosci. 2021;49:17–30.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A et al. Therapeutic Potential Psilocybin Molecules. 2021;26(10).
Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084.
Mosca A, Chiappini S, Miuli A, Mancusi G, Santovito MC, Di Carlo F, et al. Ibogaine/Noribogaine in the treatment of Substance Use disorders: a systematic review of the current literature. Curr Neuropharmacol. 2023;21(11):2178–94.
Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022;439:120302.
Wojtas A. The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacol Rep. 2023;75(6):1313–25.
IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, et al. The impact of psilocybin on patients experiencing Psychiatric symptoms: a systematic review of Randomized clinical trials. Innov Clin Neurosci. 2023;20(4–6):39–48.
Hofmann A, Heim R, Brack A, Kobel H. [Psilocybin, a psychotropic substance from the Mexican mushroom psilicybe mexicana Heim]. Experientia. 1958;14(3):107–9.
Nutt D. Psychedelic drugs-a new era in psychiatry? Dialogues Clin Neurosci. 2019;21(2):139–47.
Castro Santos H, Gama Marques J. What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomed J. 2021;6(1):e128.
Nichols DE, Psychedelics. Pharmacol Rev. 2016;68(2):264–355.
Wilcox JA. Psilocybin and obsessive compulsive disorder. J Psychoact Drugs. 2014;46(5):393–5.
Lugo-Radillo A, Md P, Cortes-Lopez JM. Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoact Drugs. 2021;53(2):146–8.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–40.
Kelmendi B, Kichuk SA, DePalmer G, Maloney G, Ching THW, Belser A, et al. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: a case report. Heliyon. 2022;8(12):e12135.
Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics Curr Biol. 2022;32(2):R63–7.
Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357–64.
Geiger HA, Wurst MG, Daniels RN. DARK classics in Chemical Neuroscience: psilocybin. ACS Chem Neurosci. 2018;9(10):2438–47.
Ray TS. Psychedelics and the human receptorome. PLoS ONE. 2010;5(2):e9019.
Coppola M, Bevione F, Mondola R. Psilocybin for Treating Psychiatric disorders: a psychonaut legend or a Promising Therapeutic Perspective? J Xenobiot. 2022;12(1):41–52.
Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J. Psilocybin as a treatment for Psychiatric illness: a Meta-analysis. Cureus. 2022;14(11):e31796.
Goel DB, Zilate S. Potential therapeutic effects of Psilocybin: a systematic review. Cureus. 2022;14(10):e30214.
Mason NL, Mischler E, Uthaug MV, Kuypers KPC. Sub-acute effects of Psilocybin on Empathy, Creative thinking, and Subjective Well-Being. J Psychoact Drugs. 2019;51(2):123–34.
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, Present, and Future. Neuropsychopharmacology. 2017;42(11):2105–13.
Latimer D, Stocker MD, Sayers K, Green J, Kaye AM, Abd-Elsayed A, et al. MDMA to treat PTSD in adults. Psychopharmacol Bull. 2021;51(3):125–49.
Mahapatra A, Gupta R. Role of psilocybin in the treatment of depression. Ther Adv Psychopharmacol. 2017;7(1):54–6.
Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front Psychol. 2022;13:873279.
Thomas K, Malcolm B, Lastra D. Psilocybin-assisted therapy: a review of a Novel Treatment for Psychiatric disorders. J Psychoact Drugs. 2017;49(5):446–55.
Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in Psychiatric Research and Development. Front Pharmacol. 2018;9:733.
Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391–410.
Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry. 2012;200(3):238–44.
Williams MT, Mugno B, Franklin M, Faber S. Symptom dimensions in obsessive-compulsive disorder: phenomenology and treatment outcomes with exposure and ritual prevention. Psychopathology. 2013;46(6):365–76.
Jalal B, Chamberlain SR, Sahakian BJ. Obsessive-compulsive disorder: etiology, neuropathology, and cognitive dysfunction. Brain Behav. 2023;13(6):e3000.
Stein DJ. Obsessive-compulsive disorder. Lancet. 2002;360(9330):397–405.
Kim SW, Dysken MW, Kuskowski M. The Yale-Brown obsessive-compulsive scale: a reliability and validity study. Psychiatry Res. 1990;34(1):99–106.
Dostal AL, Pilkington PD. Early maladaptive schemas and obsessive-compulsive disorder: a systematic review and meta-analysis. J Affect Disord. 2023;336:42–51.
Young JE, Klosko JS, Weishaar ME. Schema therapy: a practitioner’s guide. New York: The Guilford Press; 2003.
Zai G, Barta C, Cath D, Eapen V, Geller D, Grünblatt E. New insights and perspectives on the genetics of obsessive-compulsive disorder. Psychiatr Genet. 2019;29(5):142–51.
Goodman WK, Storch EA, Sheth SA. Harmonizing the neurobiology and treatment of obsessive-compulsive disorder. Am J Psychiatry. 2021;178(1):17–29.
Chamberlain BL, Ahmari SE. Animal models for OCD Research. Curr Top Behav Neurosci. 2021;49:55–96.
Lin YC, Sahoo BK, Gau SS, Yang RB. The biology of SCUBE. J Biomed Sci. 2023;30(1):33.
Cappi C, Oliphant ME, Péter Z, Zai G, Conceição do Rosário M, Sullivan CAW, et al. De Novo damaging DNA coding mutations are Associated with obsessive-compulsive disorder and overlap with Tourette’s disorder and autism. Biol Psychiatry. 2020;87(12):1035–44.
Escobar AP, Wendland JR, Chávez AE, Moya PR. The neuronal glutamate transporter EAAT3 in obsessive-compulsive disorder. Front Pharmacol. 2019;10:1362.
Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev. 2005;29(3):399–419.
Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics. 2008;2:62–75.
Fineberg NA, Apergis-Schoute AM, Vaghi MM, Banca P, Gillan CM, Voon V, et al. Mapping compulsivity in the DSM-5 obsessive compulsive and related disorders: cognitive domains, neural circuitry, and treatment. Int J Neuropsychopharmacol. 2018;21(1):42–58.
Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43–51.
Saxena S, Bota RG, Brody AL. Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry. 2001;6(2):82–101.
de Wit SJ, Alonso P, Schweren L, Mataix-Cols D, Lochner C, Menchón JM, et al. Multicenter Voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. Am J Psychiatry. 2014;171(3):340–9.
Fouche JP, du Plessis S, Hattingh C, Roos A, Lochner C, Soriano-Mas C, et al. Cortical thickness in obsessive-compulsive disorder: multisite mega-analysis of 780 brain scans from six centres. Br J Psychiatry. 2017;210(1):67–74.
Boedhoe PS, Schmaal L, Abe Y, Ameis SH, Arnold PD, Batistuzzo MC, et al. Distinct subcortical volume alterations in Pediatric and Adult OCD: a Worldwide Meta- and Mega-analysis. Am J Psychiatry. 2017;174(1):60–9.
Radua J, Grau M, van den Heuvel OA, Thiebaut de Schotten M, Stein DJ, Canales-Rodríguez EJ, et al. Multimodal Voxel-based meta-analysis of white matter abnormalities in obsessive-compulsive disorder. Neuropsychopharmacology. 2014;39(7):1547–57.
Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci. 2008;33(5):405–12.
Thorsen AL, Hagland P, Radua J, Mataix-Cols D, Kvale G, Hansen B, et al. Emotional Processing in Obsessive-compulsive disorder: a systematic review and Meta-analysis of 25 functional neuroimaging studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(6):563–71.
Rasgon A, Lee WH, Leibu E, Laird A, Glahn D, Goodman W, et al. Neural correlates of affective and non-affective cognition in obsessive compulsive disorder: a meta-analysis of functional imaging studies. Eur Psychiatry. 2017;46:25–32.
Gillan CM, Robbins TW, Sahakian BJ, van den Heuvel OA, van Wingen G. The role of habit in compulsivity. Eur Neuropsychopharmacol. 2016;26(5):828–40.
Stein DJ, Arya M, Pietrini P, Rapoport JL, Swedo SE. Neurocircuitry of disgust and anxiety in obsessive-compulsive disorder: a positron emission tomography study. Metab Brain Dis. 2006;21(2–3):267–77.
Courtiol E, Menezes EC, Teixeira CM. Serotonergic regulation of the dopaminergic system: implications for reward-related functions. Neurosci Biobehav Rev. 2021;128:282–93.
Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience. 1998;82(2):443–68.
Kim M, Kwak S, Yoon YB, Kwak YB, Kim T, Cho KIK, et al. Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Neuropsychopharmacology. 2019;44(12):2073–81.
Nikolaus S, Antke C, Beu M, Müller HW, Cortical GABA. Striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders–results from in vivo imaging studies. Rev Neurosci. 2010;21(2):119–39.
Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Schmidl-Mohl B, et al. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology. 2007;32(8):1661–8.
Kim E, Howes OD, Park JW, Kim SN, Shin SA, Kim BH, et al. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11 C]DASB PET study. Psychol Med. 2016;46(2):357–66.
Müller-Vahl KR, Szejko N, Wilke F, Jakubovski E, Geworski L, Bengel F, et al. Serotonin transporter binding is increased in Tourette syndrome with obsessive compulsive disorder. Sci Rep. 2019;9(1):972.
Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, et al. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry. 2003;54(12):1414–21.
Hesse S, Stengler K, Regenthal R, Patt M, Becker GA, Franke A, et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2011;14(5):606–17.
Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11 C]DASB PET study. J Neural Transm (Vienna). 2007;114(12):1603–9.
Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11 C]DASB PET study. NeuroImage. 2010;49(1):121–6.
Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology. 2008;33(13):3126–34.
Stein DJ, Koen N, Fineberg N, Fontenelle LF, Matsunaga H, Osser D, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep. 2012;14(3):211–9.
Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 Suppl):5–53.
Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci. 1998;112(6):1475–85.
Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res. 1990;33(1):83–94.
Grant JE, Hook R, Valle S, Chesivoir E, Chamberlain SR. Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial. Int Clin Psychopharmacol. 2021;36(5):225–9.
Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS. Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging. 2003;30(12):1637–43.
Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65 Suppl 14:11– 7.
van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry. 2004;161(12):2201–6.
Karthik S, Sharma LP, Narayanaswamy JC. Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2020;16:1003–13.
Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1146–53.
Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive-compulsive disorder. Indian J Psychiatry. 2019;61(Suppl 1):S58–65.
Guo JD, O’Flaherty BM, Rainnie DG. Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. Neuropharmacology. 2017;126:224–32.
Swierkosz-Lenart K, Dos Santos JFA, Elowe J, Clair AH, Bally JF, Riquier F, et al. Therapies for obsessive-compulsive disorder: current state of the art and perspectives for approaching treatment-resistant patients. Front Psychiatry. 2023;14:1065812.
Mączka G Psychoterapia poznawczo-behawioralna (CBT). 2021 [Access: 2023, July 17, https://www.centrumdobrejterapii.pl/materialy/psychoterapia-poznawczo-behawioralna-cbt/].
Spencer SD, Stiede JT, Wiese AD, Goodman WK, Guzick AG, Storch EA. Cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatr Clin North Am. 2023;46(1):167–80.
Kotzalidis GD, Del Casale A, Simmaco M, Pancheri L, Brugnoli R, Paolini M, et al. Placebo effect in obsessive-compulsive disorder (OCD). Placebo response and Placebo responders in OCD: the Trend Over Time. Curr Neuropharmacol. 2019;17(8):741–74.
Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, Blakely RD. Cloning and expression of the mouse serotonin transporter. Brain Res Mol Brain Res. 1996;43(1–2):185–92.
Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol. 2009;16(6):652–7.
Pittenger C. Pharmacotherapeutic strategies and new targets in OCD. Curr Top Behav Neurosci. 2021;49:331–84.
Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533–40.
Clomipramine in the. Treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry. 1991;48(8):730–8.
Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151–61.
Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000;6(3):113–28.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry. 2002;63(11):1004–9.
Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2003;64(5):546–50.
Bokor G, Anderson PD. Obsessive-compulsive disorder. J Pharm Pract. 2014;27(2):116–30.
Grady TA, Pigott TA, L’Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150(5):819–21.
McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1993;150(4):647–9.
Pigott TA, L’Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol. 1992;12(1):11–8.
Sassano-Higgins SA, Pato MT. Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: a meta-analysis. J Pharmacol Pharmacother. 2015;6(1):36–8.
Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, et al. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol. 2015;30(2):70–84.
Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004;65(10):1394–9.
Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515–20.
Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update Meta-analysis of Double-Blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015;18(9).
Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602.
Andrade C. Augmentation with Memantine in Obsessive-compulsive disorder. J Clin Psychiatry. 2019;80(6).
Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72(3):543–62.
Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907–21.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an International Expert Opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–99.
Martinotti G, Chiappini S, Pettorruso M, Mosca A, Miuli A, Di Carlo F et al. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sci. 2021;11(7).
Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475–83.
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study. National Library of Medicine (US). 2018, November 13–2024, December 15 [ClinicalTrials.gov. Identifier NCT03356483, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT03356483].
Psilocybin for Treatment of Obsessive Compulsive Disorder. National Library of Medicine (US). 2019, January 02–2023, December 30 [ClinicalTrials.gov Identifier NCT03300947, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT03300947].
PsilOCD: A Pharmacological-Challenge Feasibility Study. National Library of Medicine (US). 2022, October 28–2024, July 30 [ClinicalTrials.gov. Identifier NCT06258031, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT06258031].
Effects of Psilocybin in Obsessive Compulsive Disorder. National Library of Medicine (US). 2022, November 28–2026, September 12 [ClinicalTrials.gov. Identifier NCT05546658, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT05546658].
Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD. National Library of Medicine (US). 2023, May 01–2025, December 01 [ClinicalTrials.gov. Identifier NCT04882839, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT04882839].
Effects of Repeated Psilocybin Dosing in OCD. National Library of Medicine (US). 2023, July 20–2027, July [ClinicalTrials.gov. Identifier NCT05370911, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT05370911].
Feasibility C, Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD. National Library of Medicine (US).; 2024, April– 2024, September [ClinicalTrials.gov. Identifier NCT06299319, Access: 2024, April 15, https://clinicaltrials.gov/study/NCT06299319].
Sard H, Kumaran G, Morency C, Roth BL, Toth BA, He P, et al. SAR of psilocybin analogs: discovery of a selective 5-HT 2 C agonist. Bioorg Med Chem Lett. 2005;15(20):4555–9.
Matsushima Y, Shirota O, Kikura-Hanajiri R, Goda Y, Eguchi F. Effects of Psilocybe argentipes on marble-burying behavior in mice. Biosci Biotechnol Biochem. 2009;73(8):1866–8.
Singh S, Botvinnik A, Shahar O, Wolf G, Yakobi C, Saban M, et al. Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Transl Psychiatry. 2023;13(1):164.
Odland AU, Kristensen JL, Andreasen JT. Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice. Behav Brain Res. 2021;401:113093.
Delay J, Pichot P, Lemperiere T, Quetin AM. [Therapeutic effect of psilocybin on convulsive neurosis]. Ann Med Psychol (Paris). 1959;117(2):509–15.
Leonard HL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry. 1987;144(9):1239–40.
Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 1997;154(7):1037–8.
Perrine DM. Hallucinogens and obsessive-compulsive disorder. Am J Psychiatry. 1999;156(7):1123.
Ching THW, Grazioplene R, Bohner C, Kichuk SA, DePalmer G, D’Amico E, et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023;14:1178529.
Ching THW, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, et al. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Front Psychiatry. 2023;14:1278823.
Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187.
Delli Pizzi S, Chiacchiaretta P, Sestieri C, Ferretti A, Tullo MG, Della Penna S, et al. LSD-induced changes in the functional connectivity of distinct thalamic nuclei. NeuroImage. 2023;283:120414.
Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31(9):1091–120.
Martin DA, Nichols CD. The effects of Hallucinogens on Gene expression. Curr Top Behav Neurosci. 2018;36:137–58.
Lerer E, Botvinnik A, Shahar O, Grad M, Blakolmer K, Shomron N, et al. Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulators. Front Pharmacol. 2024;15:1391412.
Urban MM, Stingl MR, Meinhardt MW. Mini-review: the neurobiology of treating substance use disorders with classical psychedelics. Front Neurosci. 2023;17:1156319.
Kähönen J. Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences. Front Psychol. 2023;14:1104627.
Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a Unified Model of the Brain Action of Psychedelics. Pharmacol Rev. 2019;71(3):316–44.
Acevedo EC, Uhler S, White KP, Al-Shawaf L. What predicts beneficial outcomes in psychedelic use? A Quantitative Content Analysis of Psychedelic Health Outcomes. J Psychoact Drugs. 2024:1–10.
Yerubandi A, Thomas JE, Bhuiya N, Harrington C, Villa Zapata L, Caballero J. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and Meta-analysis. JAMA Netw Open. 2024;7(4):e245960.
Wsół A. Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep. 2023;75(6):1362–80.
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172(2):145–56.
MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217.
Fitzpatrick CM, Anderson BT, Agin-Liebes G, Guydish J. Comment and response: (Lugo-Radillo & Cortez-Lopez, 2020) long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoact Drugs. 2022;54(4):324–7.
Halpern JH, Lerner AG, Passie T. A review of Hallucinogen Persisting Perception Disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Top Behav Neurosci. 2018;36:333–60.
Bates MLS, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacol Biochem Behav. 2021;203:173129.
Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-Jones M, Schlosser D, et al. Optimizing outcomes in psilocybin therapy: considerations in participant evaluation and preparation. J Affect Disord. 2023;326:18–25.
Funding
This work did not receive funding from any sources.
Author information
Authors and Affiliations
Contributions
M.O-L. prepared the main text of the manuscript. K.K. revised the work critically, provided valuable comments, and supervised the process. B.B., D.M-G., and A.C-J. revised the work critically and provided valuable comments. All authors reviewed the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
All authors declare that they have no conflicts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Owe-Larsson, M., Kamińska, K., Buchalska, B. et al. Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacol. Rep 76, 911–925 (2024). https://doi.org/10.1007/s43440-024-00633-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43440-024-00633-1